A Phase 2, Randomized, Double-blind, Multi-center, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-498 in Female Patients With Androgenetic Alopecia
Latest Information Update: 15 Jul 2024
At a glance
- Drugs CKD-498 (Primary)
- Indications Alopecia
- Focus Therapeutic Use
- Sponsors Chong Kun Dang
Most Recent Events
- 28 Jun 2024 Status changed from recruiting to completed.
- 16 Jan 2023 New trial record